var data={"title":"Clinical features of the carcinoid syndrome","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Clinical features of the carcinoid syndrome</div><dl id=\"topicContributors\"><dt><span> </span>Author:</dt><dd><a href=\"https://www.uptodate.com/contents/clinical-features-of-the-carcinoid-syndrome/contributors\" class=\"contributor contributor_credentials\">Jonathan R Strosberg, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a href=\"https://www.uptodate.com/contents/clinical-features-of-the-carcinoid-syndrome/contributors\" class=\"contributor contributor_credentials\">Kenneth K Tanabe, MD</a></dd><dd><a href=\"https://www.uptodate.com/contents/clinical-features-of-the-carcinoid-syndrome/contributors\" class=\"contributor contributor_credentials\">David C Whitcomb, MD, PhD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/clinical-features-of-the-carcinoid-syndrome/contributors\" class=\"contributor contributor_credentials\">Diane MF Savarese, MD</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/clinical-features-of-the-carcinoid-syndrome/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Jun 05, 2017.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H1\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Carcinoid syndrome is the term applied to a constellation of symptoms mediated by various humoral factors elaborated by some well-differentiated neuroendocrine tumors (NETs) of the digestive tract and lungs, which synthesize, store, and release a variety of polypeptides, biogenic amines, and prostaglandins (<a href=\"image.htm?imageKey=ENDO%2F79329\" class=\"graphic graphic_table graphicRef79329 \">table 1</a>). Some of these tumor products are responsible for the carcinoid syndrome, but the relative contributions of each and the specificity of any for particular components of the syndrome are uncertain (<a href=\"image.htm?imageKey=ENDO%2F63079\" class=\"graphic graphic_table graphicRef63079 \">table 2</a>).</p><p>The pathophysiology and clinical manifestations of the carcinoid syndrome will be reviewed here. The diagnosis and treatment of this disorder are discussed separately. (See <a href=\"topic.htm?path=diagnosis-of-the-carcinoid-syndrome-and-tumor-localization\" class=\"medical medical_review\">&quot;Diagnosis of the carcinoid syndrome and tumor localization&quot;</a> and <a href=\"topic.htm?path=staging-treatment-and-posttreatment-surveillance-of-nonmetastatic-well-differentiated-gastrointestinal-tract-neuroendocrine-carcinoid-tumors\" class=\"medical medical_review\">&quot;Staging, treatment, and posttreatment surveillance of nonmetastatic, well-differentiated gastrointestinal tract neuroendocrine (carcinoid) tumors&quot;</a> and <a href=\"topic.htm?path=metastatic-well-differentiated-gastroenteropancreatic-neuroendocrine-tumors-presentation-prognosis-imaging-and-biochemical-monitoring\" class=\"medical medical_review\">&quot;Metastatic well-differentiated gastroenteropancreatic neuroendocrine tumors: Presentation, prognosis, imaging, and biochemical monitoring&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H1790249289\"><span class=\"h1\">FREQUENCY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Neuroendocrine tumors (NETs) may arise anywhere in the gastrointestinal tract, in the lungs, and occasionally, elsewhere (<a href=\"image.htm?imageKey=ENDO%2F56015\" class=\"graphic graphic_table graphicRef56015 \">table 3</a>). Carcinoid syndrome is most common in the setting of disseminated disease, particularly liver metastases, but it can occur in apparently locoregional disease. One reason may be understaging. Unappreciated hepatic metastases may be more common than previously reported [<a href=\"https://www.uptodate.com/contents/clinical-features-of-the-carcinoid-syndrome/abstract/1-3\" class=\"abstract_t\">1-3</a>], especially in small bowel primaries.</p><p>The liver inactivates bioactive products secreted into the portal circulation. This may explain why patients with gastrointestinal NETs most often develop carcinoid syndrome if they have hepatic metastases, resulting in the secretion of tumor products into the systemic circulation [<a href=\"https://www.uptodate.com/contents/clinical-features-of-the-carcinoid-syndrome/abstract/4\" class=\"abstract_t\">4</a>]. In the large majority of cases, carcinoid syndrome is associated with metastatic tumors originating in the midgut (jejunum, ileum, and cecum); however, the expression is variable in individual patients [<a href=\"https://www.uptodate.com/contents/clinical-features-of-the-carcinoid-syndrome/abstract/5\" class=\"abstract_t\">5</a>]. Less often, carcinoid syndrome is caused by a NET arising in the lung or in the distal colon or rectum (foregut and hindgut embryologic origin, respectively) [<a href=\"https://www.uptodate.com/contents/clinical-features-of-the-carcinoid-syndrome/abstract/6\" class=\"abstract_t\">6</a>]. Gastric and lung NETs may be associated with atypical carcinoid syndromes. (See <a href=\"#H15\" class=\"local\">'Variant syndromes'</a> below.)</p><p>Approximately 1 percent of pancreatic NETs secrete excess serotonin and other vasoactive substances that produce the carcinoid syndrome. (See <a href=\"topic.htm?path=clinical-characteristics-of-well-differentiated-neuroendocrine-carcinoid-tumors-arising-in-the-tubular-digestive-tract-lung-and-genitourinary-tract\" class=\"medical medical_review\">&quot;Clinical characteristics of well-differentiated neuroendocrine (carcinoid) tumors arising in the tubular digestive tract, lung, and genitourinary tract&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H2\"><span class=\"h1\">PATHOPHYSIOLOGY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>As many as 40 secretory products have been identified in various gastroenteropancreatic neuroendocrine tumors (NETs) [<a href=\"https://www.uptodate.com/contents/clinical-features-of-the-carcinoid-syndrome/abstract/4\" class=\"abstract_t\">4</a>]. The most prominent of these are serotonin, histamine, tachykinins, kallikrein, and prostaglandins (<a href=\"image.htm?imageKey=ENDO%2F79329\" class=\"graphic graphic_table graphicRef79329 \">table 1</a>). </p><p class=\"headingAnchor\" id=\"H3\"><span class=\"h2\">Tryptophan metabolism</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Altered metabolism of tryptophan occurs in almost all patients with the carcinoid syndrome. In normal subjects, approximately 1 percent of dietary tryptophan is converted to serotonin; however, this value may increase to 70 percent or more in patients with the carcinoid syndrome [<a href=\"https://www.uptodate.com/contents/clinical-features-of-the-carcinoid-syndrome/abstract/7\" class=\"abstract_t\">7</a>]. Serotonin is then metabolized to 5-hydroxyindoleacetic acid (5-HIAA) (<a href=\"image.htm?imageKey=ENDO%2F51368\" class=\"graphic graphic_figure graphicRef51368 \">figure 1</a>).</p><p>However, some foregut NETs (gastric, lung (<a href=\"image.htm?imageKey=ONC%2F83185\" class=\"graphic graphic_figure graphicRef83185 \">figure 2</a>)) lack the aromatic amino acid decarboxylase that converts 5-hydroxytryptophan to serotonin [<a href=\"https://www.uptodate.com/contents/clinical-features-of-the-carcinoid-syndrome/abstract/5\" class=\"abstract_t\">5</a>]; these tumors produce 5-hydroxytryptophan (and histamine) instead of serotonin. Hindgut NETs (distal colon and rectum) rarely secrete serotonin or any other bioactive hormones and are, therefore, unassociated with hormonal syndromes, even when metastatic (<a href=\"image.htm?imageKey=ENDO%2F56015\" class=\"graphic graphic_table graphicRef56015 \">table 3</a>)&nbsp;[<a href=\"https://www.uptodate.com/contents/clinical-features-of-the-carcinoid-syndrome/abstract/5\" class=\"abstract_t\">5</a>]. </p><p>These alterations in tryptophan metabolism can explain many of the findings in the carcinoid syndrome.</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The diversion of tryptophan to the synthesis of serotonin in patients with widely metastatic tumors may result in niacin deficiency. This disorder may be characterized by decreased protein synthesis and hypoalbuminemia, with or without the clinical manifestations of pellagra (rough scaly skin, glossitis, angular stomatitis, and mental confusion) [<a href=\"https://www.uptodate.com/contents/clinical-features-of-the-carcinoid-syndrome/abstract/8\" class=\"abstract_t\">8</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Tumor production of serotonin is the most likely cause of the diarrhea in carcinoid syndrome. Serotonin stimulates intestinal secretion and motility and inhibits intestinal absorption [<a href=\"https://www.uptodate.com/contents/clinical-features-of-the-carcinoid-syndrome/abstract/9,10\" class=\"abstract_t\">9,10</a>].</p><p/><p>Serotonin may also stimulate fibroblast growth and fibrogenesis. These effects can lead to the peritoneal and cardiac valvular fibrosis associated with the carcinoid syndrome [<a href=\"https://www.uptodate.com/contents/clinical-features-of-the-carcinoid-syndrome/abstract/11\" class=\"abstract_t\">11</a>]. (See <a href=\"#H13\" class=\"local\">'Cardiac valvular lesions'</a> below.)&nbsp;</p><p>Serotonin does not cause flushing [<a href=\"https://www.uptodate.com/contents/clinical-features-of-the-carcinoid-syndrome/abstract/12\" class=\"abstract_t\">12</a>]. Among the potential mediators are bradykinins, prostaglandins, tachykinins, substance P, <span class=\"nowrap\">and/or</span> histamine [<a href=\"https://www.uptodate.com/contents/clinical-features-of-the-carcinoid-syndrome/abstract/13\" class=\"abstract_t\">13</a>].</p><p class=\"headingAnchor\" id=\"H4\"><span class=\"h2\">Histamine</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Primary gastric NETs can produce histamine, which may be responsible for the atypical flushing and pruritus associated with these tumors (see <a href=\"#H16\" class=\"local\">'Gastric NET variant syndrome'</a> below). The observation that such flushing can be ameliorated by combined H1 and H2 antagonism is compatible with this hypothesis [<a href=\"https://www.uptodate.com/contents/clinical-features-of-the-carcinoid-syndrome/abstract/12\" class=\"abstract_t\">12</a>]. </p><p class=\"headingAnchor\" id=\"H5\"><span class=\"h2\">Kallikrein</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Some NETs produce kallikrein, a protein that cleaves kinin from plasma kininogens. Bradykinin, a short-lived product of this cleavage, is a potent vasodilator and may be responsible for flushing in some carcinoid patients [<a href=\"https://www.uptodate.com/contents/clinical-features-of-the-carcinoid-syndrome/abstract/14\" class=\"abstract_t\">14</a>]. Kinins also stimulate intestinal motility and increase vascular permeability [<a href=\"https://www.uptodate.com/contents/clinical-features-of-the-carcinoid-syndrome/abstract/15\" class=\"abstract_t\">15</a>].</p><p class=\"headingAnchor\" id=\"H6\"><span class=\"h2\">Prostaglandins</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Prostaglandins E and F stimulate intestinal motility and fluid secretion in the normal gastrointestinal tract [<a href=\"https://www.uptodate.com/contents/clinical-features-of-the-carcinoid-syndrome/abstract/16\" class=\"abstract_t\">16</a>]. Although elevated serum prostaglandin concentrations are found in patients with the carcinoid syndrome, their role in the symptomatology of this disorder is uncertain [<a href=\"https://www.uptodate.com/contents/clinical-features-of-the-carcinoid-syndrome/abstract/17\" class=\"abstract_t\">17</a>].</p><p class=\"headingAnchor\" id=\"H7\"><span class=\"h2\">Tachykinins</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Some NETs secrete tachykinins (substance P, neurokinin A, neuropeptide K). Elevations in the serum concentrations of these latter polypeptides may contribute to flushing and diarrhea [<a href=\"https://www.uptodate.com/contents/clinical-features-of-the-carcinoid-syndrome/abstract/18-20\" class=\"abstract_t\">18-20</a>]. </p><p class=\"headingAnchor\" id=\"H8\"><span class=\"h1\">CLINICAL FEATURES</span></p><p class=\"headingAnchor\" id=\"H9\"><span class=\"h2\">Cutaneous flushing</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Episodic flushing is the clinical hallmark of the carcinoid syndrome and occurs in 85 percent of patients. The typical flush associated with midgut neuroendocrine tumors (NETs; jejunum, ileum, cecum, appendix) begins suddenly and lasts from 30 seconds to as long as 30 minutes. It primarily involves the face, neck, and upper chest, which become red to violaceous or purple, and is associated with a mild burning sensation (<a href=\"image.htm?imageKey=ENDO%2F55493\" class=\"graphic graphic_picture graphicRef55493 \">picture 1</a>). Severe flushes are accompanied by a fall in blood pressure and rise in pulse rate. As the disease progresses, the episodes may last longer, and the flushing may be more diffuse. The differential diagnosis of flushing is listed in the table (<a href=\"image.htm?imageKey=ENDO%2F78237\" class=\"graphic graphic_table graphicRef78237 \">table 4</a>). </p><p>Most flushing episodes occur spontaneously, but they can be provoked by eating, drinking alcohol, defecation, emotional events, palpation of the liver, and anesthesia [<a href=\"https://www.uptodate.com/contents/clinical-features-of-the-carcinoid-syndrome/abstract/21-23\" class=\"abstract_t\">21-23</a>]. Episodes induced by anesthesia may last hours and be accompanied by severe hypotension (&quot;carcinoid crisis&quot;). This problem can be minimized by pretreatment with <a href=\"topic.htm?path=octreotide-drug-information\" class=\"drug drug_general\">octreotide</a> [<a href=\"https://www.uptodate.com/contents/clinical-features-of-the-carcinoid-syndrome/abstract/23\" class=\"abstract_t\">23</a>]. (See <a href=\"topic.htm?path=treatment-of-the-carcinoid-syndrome#H624742810\" class=\"medical medical_review\">&quot;Treatment of the carcinoid syndrome&quot;, section on 'Prevention and management of carcinoid crisis'</a>.)</p><p class=\"headingAnchor\" id=\"H10\"><span class=\"h2\">Venous telangiectasia</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>These purplish vascular lesions, similar to those seen in acne rosacea, appear late in the course of the carcinoid syndrome. They are due to prolonged vasodilatation and most often occur on the nose, upper lip, and malar areas.</p><p class=\"headingAnchor\" id=\"H11\"><span class=\"h2\">Diarrhea</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Secretory diarrhea occurs in 80 percent of patients and is often the most debilitating component of the syndrome. Stools may vary from few to more than 30 per day, are typically watery and nonbloody, and can be explosive and accompanied by abdominal cramping. The abdominal cramps may be a consequence of mesenteric fibrosis or intestinal blockage by the primary tumor. The diarrhea is usually unrelated to flushing episodes. Transit time through the intestine may be extremely short [<a href=\"https://www.uptodate.com/contents/clinical-features-of-the-carcinoid-syndrome/abstract/10\" class=\"abstract_t\">10</a>].</p><p class=\"headingAnchor\" id=\"H12\"><span class=\"h2\">Bronchospasm</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Ten to 20 percent of patients with the carcinoid syndrome have wheezing and dyspnea, often during flushing episodes. Carcinoid wheezing should not be mistaken for bronchial asthma because treatment with beta agonists can trigger intense, prolonged vasodilation [<a href=\"https://www.uptodate.com/contents/clinical-features-of-the-carcinoid-syndrome/abstract/24\" class=\"abstract_t\">24</a>].</p><p class=\"headingAnchor\" id=\"H13\"><span class=\"h2\">Cardiac valvular lesions</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Carcinoid heart disease is characterized by pathognomonic plaque-like deposits of fibrous tissue. These deposits occur most commonly on the endocardium of valvular cusps, the cardiac chambers, and occasionally, the intima of the pulmonary arteries or aorta (<a href=\"image.htm?imageKey=ENDO%2F74687\" class=\"graphic graphic_figure graphicRef74687 \">figure 3</a>). The valves and endocardium of the right side of the heart are most often affected because inactivation of humoral substances by the lung protects the left heart. The clinical manifestations and treatment of carcinoid heart disease are discussed separately. (See <a href=\"topic.htm?path=carcinoid-heart-disease\" class=\"medical medical_review\">&quot;Carcinoid heart disease&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H14\"><span class=\"h2\">Minor manifestations</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>There are a number of minor manifestations associated with the carcinoid syndrome:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>As noted above, diversion of dietary tryptophan for synthesis of large amounts of serotonin can very rarely result in the development of pellagra [<a href=\"https://www.uptodate.com/contents/clinical-features-of-the-carcinoid-syndrome/abstract/8\" class=\"abstract_t\">8</a>], manifested by rough scaly skin, glossitis, angular stomatitis, and mental confusion. Poor dietary intake, and diarrhea or malabsorption can augment this process.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Muscle wasting may occur as a result of poor protein synthesis.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In addition to the mesenteric fibrosis associated with NETs, extensive fibrosis can occur in the retroperitoneal area and other sites, causing ureteral obstruction [<a href=\"https://www.uptodate.com/contents/clinical-features-of-the-carcinoid-syndrome/abstract/25,26\" class=\"abstract_t\">25,26</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Persistent brawny edema of the face and, to a lesser degree, of the extremities may be an advanced manifestation of the syndrome in some patients with severe flushing attacks. This is particularly true for those with foregut NETs [<a href=\"https://www.uptodate.com/contents/clinical-features-of-the-carcinoid-syndrome/abstract/27\" class=\"abstract_t\">27</a>].</p><p/><p class=\"headingAnchor\" id=\"H15\"><span class=\"h1\">VARIANT SYNDROMES</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Some patients with functioning gastric or lung neuroendocrine tumors (NETs) have clinical and biochemical variations from the classic syndrome.</p><p class=\"headingAnchor\" id=\"H16\"><span class=\"h2\">Gastric NET variant syndrome</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>In patients with the gastric NET variant, the flushes may be patchy, sharply demarcated, serpiginous, and cherry red; they are also intensely pruritic. Diarrhea or cardiac lesions are unusual. The tumors that cause this variant syndrome secrete histamine [<a href=\"https://www.uptodate.com/contents/clinical-features-of-the-carcinoid-syndrome/abstract/28,29\" class=\"abstract_t\">28,29</a>].</p><p class=\"headingAnchor\" id=\"H17\"><span class=\"h2\">Lung NET variant syndrome</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>In patients with the lung NET variant, the flushes can be very severe and prolonged, lasting hours to days [<a href=\"https://www.uptodate.com/contents/clinical-features-of-the-carcinoid-syndrome/abstract/27\" class=\"abstract_t\">27</a>]. They may be associated with disorientation, anxiety, and tremor. Periorbital edema, lacrimation, salivation, hypotension, tachycardia, diarrhea, dyspnea, asthma, edema, and oliguria are other components of this variant. The specific hormone mediator of flushing in patients with lung NETs is unclear, but it could be histamine. In some cases, blood serotonin or urine 5-hydroxyindoleacetic acid (5-HIAA) levels are normal. (See <a href=\"topic.htm?path=lung-neuroendocrine-carcinoid-tumors-epidemiology-risk-factors-classification-histology-diagnosis-and-staging\" class=\"medical medical_review\">&quot;Lung neuroendocrine (carcinoid) tumors: Epidemiology, risk factors, classification, histology, diagnosis, and staging&quot;</a>.) </p><p class=\"headingAnchor\" id=\"H18\"><span class=\"h1\">SUMMARY</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Seventy-five to 80 percent of patients with carcinoid syndrome have small bowel primary neuroendocrine tumors (NETs); however, the manifestations and severity vary in individual patients [<a href=\"https://www.uptodate.com/contents/clinical-features-of-the-carcinoid-syndrome/abstract/5\" class=\"abstract_t\">5</a>]. Gastric and lung NETs are sometimes associated with atypical carcinoid syndromes (see below).</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Among patients with NETs, the carcinoid syndrome is most common in the presence of liver metastases, but it can occur in locoregional disease. It is less common overall with gastric and lung NETs, as well as in those NETs arising in the hindgut (distal colon and rectum). (See <a href=\"#H1790249289\" class=\"local\">'Frequency'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Episodic flushing is the clinical hallmark of the carcinoid syndrome and occurs in 85 percent of patients. The typical flush associated with midgut NETs (jejunum, ileum, cecum, appendix) begins suddenly and often lasts 20 to 30 seconds. It primarily involves the face, neck, and upper chest, which become red to violaceous or purple, and is associated with a mild burning sensation (<a href=\"image.htm?imageKey=ENDO%2F55493\" class=\"graphic graphic_picture graphicRef55493 \">picture 1</a>). Severe flushes are accompanied by a fall in blood pressure and rise in pulse rate. As the disease progresses, the episodes may last longer, and the flushing may be more diffuse. The differential diagnosis of flushing is listed in the table (<a href=\"image.htm?imageKey=ENDO%2F78237\" class=\"graphic graphic_table graphicRef78237 \">table 4</a>). (See <a href=\"#H8\" class=\"local\">'Clinical features'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Diarrhea is a prominent complaint in the majority of patients with carcinoid syndrome and is due to rapid intestinal transit time. Right-sided valvular heart disease affects as many as 40 percent of patients. A minority may experience bronchospasm. </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Some patients with functioning gastric or lung NETs have clinical and biochemical variations from the classic syndrome.</p><p/><p><strong>ACKNOWLEDGMENT</strong> &mdash; The editorial staff at UpToDate would like to acknowledge Stephen Goldfinger, MD, who contributed to an earlier version of this topic review.</p></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/clinical-features-of-the-carcinoid-syndrome/abstract/1\" class=\"nounderline abstract_t\">Datta S, Williams N, Suortamo S, et al. Carcinoid syndrome from small bowel endocrine carcinoma in the absence of hepatic metastasis. Age Ageing 2011; 40:760.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-of-the-carcinoid-syndrome/abstract/2\" class=\"nounderline abstract_t\">Feldman JM, Jones RS. Carcinoid syndrome from gastrointestinal carcinoids without liver metastasis. Ann Surg 1982; 196:33.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-of-the-carcinoid-syndrome/abstract/3\" class=\"nounderline abstract_t\">Haq AU, Yook CR, Hiremath V, Kasimis BS. Carcinoid syndrome in the absence of liver metastasis: a case report and review of literature. Med Pediatr Oncol 1992; 20:221.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-of-the-carcinoid-syndrome/abstract/4\" class=\"nounderline abstract_t\">Modlin IM, Kidd M, Latich I, et al. Current status of gastrointestinal carcinoids. Gastroenterology 2005; 128:1717.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-of-the-carcinoid-syndrome/abstract/5\" class=\"nounderline abstract_t\">Feldman JM. Carcinoid tumors and syndrome. Semin Oncol 1987; 14:237.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-of-the-carcinoid-syndrome/abstract/6\" class=\"nounderline abstract_t\">Halperin DM, Shen C, Dasari A, et al. Frequency of carcinoid syndrome at neuroendocrine tumour diagnosis: a population-based study. Lancet Oncol 2017; 18:525.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-of-the-carcinoid-syndrome/abstract/7\" class=\"nounderline abstract_t\">Kvols LK. Metastatic carcinoid tumors and the malignant carcinoid syndrome. Ann N Y Acad Sci 1994; 733:464.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-of-the-carcinoid-syndrome/abstract/8\" class=\"nounderline abstract_t\">Swain CP, Tavill AS, Neale G. Studies of tryptophan and albumin metabolism in a patient with carcinoid syndrome, pellagra, and hypoproteinemia. Gastroenterology 1976; 71:484.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-of-the-carcinoid-syndrome/abstract/9\" class=\"nounderline abstract_t\">HENDRIX TR, ATKINSON M, CLIFTON JA, INGELFINGER FJ. The effect of 5-hydroxytryptamine on intestinal motor function in man. Am J Med 1957; 23:886.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-of-the-carcinoid-syndrome/abstract/10\" class=\"nounderline abstract_t\">von der Ohe MR, Camilleri M, Kvols LK, Thomforde GM. Motor dysfunction of the small bowel and colon in patients with the carcinoid syndrome and diarrhea. N Engl J Med 1993; 329:1073.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-of-the-carcinoid-syndrome/abstract/11\" class=\"nounderline abstract_t\">Lie JP. Carcinoid tumor, carcinoid syndrome, and carcinoid heart disease. Prim Cardiol 1982; 8:163.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-of-the-carcinoid-syndrome/abstract/12\" class=\"nounderline abstract_t\">Roberts LJ 2nd, Marney SR Jr, Oates JA. Blockade of the flush associated with metastatic gastric carcinoid by combined histamine H1 and H2 receptor antagonists. Evidence for an important role of H2 receptors in human vasculature. N Engl J Med 1979; 300:236.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-of-the-carcinoid-syndrome/abstract/13\" class=\"nounderline abstract_t\">Grahame-Smith DG. What is the cause of the carcinoid flush? Gut 1987; 28:1413.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-of-the-carcinoid-syndrome/abstract/14\" class=\"nounderline abstract_t\">Oates JA, Pettinger WA, Doctor RB. Evidence for the release of bradykinin in carcinoid syndrome. J Clin Invest 1966; 45:173.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-of-the-carcinoid-syndrome/abstract/15\" class=\"nounderline abstract_t\">Oates JA. The carcinoid syndrome. N Engl J Med 1986; 315:702.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-of-the-carcinoid-syndrome/abstract/16\" class=\"nounderline abstract_t\">Metz SA, McRae JR, Robertson RP. Prostaglandins as mediators of paraneoplastic syndromes: review and up-date. Metabolism 1981; 30:299.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-of-the-carcinoid-syndrome/abstract/17\" class=\"nounderline abstract_t\">Sandler M, Karim SM, Williams ED. Prostaglandins in amine-peptide-secreting tumours. Lancet 1968; 2:1053.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-of-the-carcinoid-syndrome/abstract/18\" class=\"nounderline abstract_t\">Vinik AI, McLeod MK, Fig LM, et al. Clinical features, diagnosis, and localization of carcinoid tumors and their management. Gastroenterol Clin North Am 1989; 18:865.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-of-the-carcinoid-syndrome/abstract/19\" class=\"nounderline abstract_t\">Makridis C, Theodorsson E, Akerstr&ouml;m G, et al. Increased intestinal non-substance P tachykinin concentrations in malignant midgut carcinoid disease. J Gastroenterol Hepatol 1999; 14:500.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-of-the-carcinoid-syndrome/abstract/20\" class=\"nounderline abstract_t\">Cunningham JL, Janson ET, Agarwal S, et al. Tachykinins in endocrine tumors and the carcinoid syndrome. Eur J Endocrinol 2008; 159:275.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-of-the-carcinoid-syndrome/abstract/21\" class=\"nounderline abstract_t\">Maton PN. The carcinoid syndrome. JAMA 1988; 260:1602.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-of-the-carcinoid-syndrome/abstract/22\" class=\"nounderline abstract_t\">T&ouml;rnebrandt K, Nobin A, Ericsson M, Thomson D. Circulation, respiration and serotonin levels in carcinoid patients during neurolept anaesthesia. Anaesthesia 1983; 38:957.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-of-the-carcinoid-syndrome/abstract/23\" class=\"nounderline abstract_t\">Marsh HM, Martin JK Jr, Kvols LK, et al. Carcinoid crisis during anesthesia: successful treatment with a somatostatin analogue. Anesthesiology 1987; 66:89.</a></li><li class=\"breakAll\">Warner RRP. Carcinoid tumors. In: Gastroenterology, Berk JE (Ed), WB Saunders, Philadelphia 1985.</li><li><a href=\"https://www.uptodate.com/contents/clinical-features-of-the-carcinoid-syndrome/abstract/25\" class=\"nounderline abstract_t\">Morin LJ, Zuerner RT. Retroperitoneal fibrosis and carcinoid tumor. JAMA 1971; 216:1647.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-of-the-carcinoid-syndrome/abstract/26\" class=\"nounderline abstract_t\">Daskalakis K, Karakatsanis A, St&aring;lberg P, et al. Clinical signs of fibrosis in small intestinal neuroendocrine tumours. Br J Surg 2017; 104:69.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-of-the-carcinoid-syndrome/abstract/27\" class=\"nounderline abstract_t\">Melmon KL, Sjoerdsma A, Mason DT. Distinctive clinical and therapeutic aspects of the syndrome associated with bronchial carcinoid tumors. Am J Med 1965; 39:568.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-of-the-carcinoid-syndrome/abstract/28\" class=\"nounderline abstract_t\">Borch K, Ahr&eacute;n B, Ahlman H, et al. Gastric carcinoids: biologic behavior and prognosis after differentiated treatment in relation to type. Ann Surg 2005; 242:64.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-of-the-carcinoid-syndrome/abstract/29\" class=\"nounderline abstract_t\">Gough DB, Thompson GB, Crotty TB, et al. Diverse clinical and pathologic features of gastric carcinoid and the relevance of hypergastrinemia. World J Surg 1994; 18:473.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 2614 Version 20.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H18\"><span>SUMMARY</span></a></li><li><a href=\"#H1\" id=\"outline-link-H1\">INTRODUCTION</a></li><li><a href=\"#H1790249289\" id=\"outline-link-H1790249289\">FREQUENCY</a></li><li><a href=\"#H2\" id=\"outline-link-H2\">PATHOPHYSIOLOGY</a><ul><li><a href=\"#H3\" id=\"outline-link-H3\">Tryptophan metabolism</a></li><li><a href=\"#H4\" id=\"outline-link-H4\">Histamine</a></li><li><a href=\"#H5\" id=\"outline-link-H5\">Kallikrein</a></li><li><a href=\"#H6\" id=\"outline-link-H6\">Prostaglandins</a></li><li><a href=\"#H7\" id=\"outline-link-H7\">Tachykinins</a></li></ul></li><li><a href=\"#H8\" id=\"outline-link-H8\">CLINICAL FEATURES</a><ul><li><a href=\"#H9\" id=\"outline-link-H9\">Cutaneous flushing</a></li><li><a href=\"#H10\" id=\"outline-link-H10\">Venous telangiectasia</a></li><li><a href=\"#H11\" id=\"outline-link-H11\">Diarrhea</a></li><li><a href=\"#H12\" id=\"outline-link-H12\">Bronchospasm</a></li><li><a href=\"#H13\" id=\"outline-link-H13\">Cardiac valvular lesions</a></li><li><a href=\"#H14\" id=\"outline-link-H14\">Minor manifestations</a></li></ul></li><li><a href=\"#H15\" id=\"outline-link-H15\">VARIANT SYNDROMES</a><ul><li><a href=\"#H16\" id=\"outline-link-H16\">Gastric NET variant syndrome</a></li><li><a href=\"#H17\" id=\"outline-link-H17\">Lung NET variant syndrome</a></li></ul></li><li><a href=\"#H18\" id=\"outline-link-H18\">SUMMARY</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"ONC/2614|FIG\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"FIGURES\">FIGURES</a></div><ul><li><a href=\"image.htm?imageKey=ENDO/51368\" class=\"graphic graphic_figure\">- Tryptophan and serotonin metabolism</a></li><li><a href=\"image.htm?imageKey=ONC/83185\" class=\"graphic graphic_figure\">- Classification neuroendocrine tumors by embryonic derivation</a></li><li><a href=\"image.htm?imageKey=ENDO/74687\" class=\"graphic graphic_figure\">- Plaques in carcinoid heart</a></li></ul></li><li><div id=\"ONC/2614|PIC\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"PICTURES\">PICTURES</a></div><ul><li><a href=\"image.htm?imageKey=ENDO/55493\" class=\"graphic graphic_picture\">- Carcinoid flush</a></li></ul></li><li><div id=\"ONC/2614|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=ENDO/79329\" class=\"graphic graphic_table\">- Products of well-differentiated neuroendocrine tumors</a></li><li><a href=\"image.htm?imageKey=ENDO/63079\" class=\"graphic graphic_table\">- Carcinoid symptoms</a></li><li><a href=\"image.htm?imageKey=ENDO/56015\" class=\"graphic graphic_table\">- Characteristics of neuroendocrine tumors</a></li><li><a href=\"image.htm?imageKey=ENDO/78237\" class=\"graphic graphic_table\">- Causes of flushing</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=carcinoid-heart-disease\" class=\"medical medical_review\">Carcinoid heart disease</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-characteristics-of-well-differentiated-neuroendocrine-carcinoid-tumors-arising-in-the-tubular-digestive-tract-lung-and-genitourinary-tract\" class=\"medical medical_review\">Clinical characteristics of well-differentiated neuroendocrine (carcinoid) tumors arising in the tubular digestive tract, lung, and genitourinary tract</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=diagnosis-of-the-carcinoid-syndrome-and-tumor-localization\" class=\"medical medical_review\">Diagnosis of the carcinoid syndrome and tumor localization</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=lung-neuroendocrine-carcinoid-tumors-epidemiology-risk-factors-classification-histology-diagnosis-and-staging\" class=\"medical medical_review\">Lung neuroendocrine (carcinoid) tumors: Epidemiology, risk factors, classification, histology, diagnosis, and staging</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=metastatic-well-differentiated-gastroenteropancreatic-neuroendocrine-tumors-presentation-prognosis-imaging-and-biochemical-monitoring\" class=\"medical medical_review\">Metastatic well-differentiated gastroenteropancreatic neuroendocrine tumors: Presentation, prognosis, imaging, and biochemical monitoring</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=staging-treatment-and-posttreatment-surveillance-of-nonmetastatic-well-differentiated-gastrointestinal-tract-neuroendocrine-carcinoid-tumors\" class=\"medical medical_review\">Staging, treatment, and posttreatment surveillance of nonmetastatic, well-differentiated gastrointestinal tract neuroendocrine (carcinoid) tumors</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=treatment-of-the-carcinoid-syndrome\" class=\"medical medical_review\">Treatment of the carcinoid syndrome</a></li></ul></div></div>","javascript":null}